In this proof-of-concept study with tumor-bearing mice, PT and 177Lu-based TRT were, therefore, applied separately, as well as in combination, to two different tumor mouse models using 177Lu-folate developed at CRS or the clinically-applied 177Lu-PSMA-617. This evidence concerns the gene FOLH1 and neoplasm.